XML 33 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENTED INFORMATION
 6 Months Ended
Jun. 30, 2022
SEGMENTED INFORMATION  
SEGMENTED INFORMATION

NOTE 11 - SEGMENTED INFORMATION

 

At June 30, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

 

 

 

BioNexus Gene Lab Corp.,

a Wyoming company

 

 

 

 

 

 

 

 

 

 

 

 

100% owned

 

 

100% owned

 

 

Bionexus Gene Lab

Sdn. Bhd.,

a Malaysian company

 

 

Chemrex Corporation

Sdn. Bhd.,

a Malaysian company

 

At June 30, 2022, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

 

For the quarter ended June 30, 2022, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

 

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Six months ended June 30, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REVENUE

 

$33,467

 

 

$5,480,579

 

 

$-

 

 

$5,514,046

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(58,372)

 

 

(4,878,813)

 

 

-

 

 

 

(4,937,185)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS (LOSS)/PROFIT

 

 

(24,905)

 

 

601,766

 

 

 

-

 

 

 

576,861

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

4,285

 

 

 

94,945

 

 

 

-

 

 

 

99,230

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(51,238)

 

 

(618,348)

 

 

(109,778)

 

 

(779,364)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(1,860)

 

 

(3,785)

 

 

-

 

 

 

(5,645)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(LOSS)/PROFIT BEFORE TAX

 

 

(73,718)

 

 

74,578

 

 

 

(109,778)

 

 

(108,918)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

-

 

 

 

(12,678)

 

 

-

 

 

 

(12,678)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET (LOSS)/PROFIT

 

$(73,718)

 

$61,900

 

 

$(109,778)

 

$(121,596)

 

 

BioNexus

Malaysia

 

 

Chemrex

 

 

BGLC

 

 

Total

 

 

 

Six months ended June 30, 2021

 

REVENUE

 

$465,470

 

 

$6,075,860

 

 

$-

 

 

$6,541,330

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COST OF REVENUE

 

 

(358,528 )

 

 

(5,132,630 )

 

 

-

 

 

 

(5,491,158 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

106,942

 

 

 

943,230

 

 

 

-

 

 

 

1,050,172

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME

 

 

3,848

 

 

 

109,068

 

 

 

-

 

 

 

112,916

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

(44,128 )

 

 

(556,619 )

 

 

(80,218 )

 

 

(680,265 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FINANCE COSTS

 

 

(2,303 )

 

 

(4,534 )

 

 

-

 

 

 

(6,837 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX

 

 

64,359

 

 

 

491,145

 

 

 

(80,218 )

 

 

475,286

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax expense

 

 

(654 )

 

 

(107,626 )

 

 

-

 

 

 

(108,280 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET PROFIT/(LOSS)

 

$63,705

 

 

$383,519

 

 

$(80,218 )

 

$367,006

 

 

 

 

As of June 30, 2022 and December 31, 2021

 

 

 

Total Assets

 

 

 Total Liabilities

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BGLC & Bionexus

 

$1,032,013

 

 

$1,167,214

 

 

$66,334

 

 

$121,586

 

Chemrex

 

 

7,336,700

 

 

 

8,407,176

 

 

 

1,480,732

 

 

 

2,273,025

 

TOTAL

 

 

8,368,713

 

 

 

9,574,390

 

 

 

1,547,066

 

 

 

2,394,611